Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DIABETES

Long-term follow-up of intensive glycaemic control in type 2 diabetes

Nature Reviews Cardiology volume 16, pages 517–518 (2019)Cite this article

Subjects

In a 15-year follow-up of the VADT study, no differences in major cardiovascular outcomes were found among individuals with type 2 diabetes mellitus who underwent either intensive or standard glucose control. These results indicate that intensification of glycaemic control might not be expected to mitigate the risk of cardiovascular events.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Clinical trials on intensive versus standard glycaemic control.

References

  1. Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633–644 (2018).

    Article  Google Scholar 

  2. Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).

    Article  CAS  Google Scholar 

  3. Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).

    Article  CAS  Google Scholar 

  4. Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009).

    Article  CAS  Google Scholar 

  5. Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).

    Article  CAS  Google Scholar 

  6. Hayward, R. A. et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 372, 2197–2206 (2015).

    Article  CAS  Google Scholar 

  7. Zoungas, S. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392–1406 (2014).

    Article  Google Scholar 

  8. Reaven, P. D. et al. Intensive glucose control in patients with type 2 diabetes − 15-year follow-up. N. Engl. J. Med. 380, 2215–2224 (2019).

    Article  CAS  Google Scholar 

  9. Patel, K. V., de Albuquerque Rocha, N. & McGuire, D. K. Diabetes medications and cardiovascular outcome trials: lessons learned. Cleve. Clin. J. Med. 84, 759–767 (2017).

    Article  Google Scholar 

  10. Das, S. R. et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J. Am. Coll. Cardiol. 72, 3200–3223 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Kershaw V. Patel & Darren K. McGuire

Authors
  1. Kershaw V. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Darren K. McGuire
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darren K. McGuire.

Ethics declarations

Competing interests

D.K.M. reports honoraria for trial leadership from AstraZeneca, Boehringer Ingelheim, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Lilly US, Merck & Co, Novo Nordisk, Pfizer and Sanofi Aventis; and honoraria for consulting for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Lilly US, Merck & Co, Metavant, Novo Nordisk, Pfizer and Sanofi Aventis. K.V.P declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, K.V., McGuire, D.K. Long-term follow-up of intensive glycaemic control in type 2 diabetes. Nat Rev Cardiol 16, 517–518 (2019). https://doi.org/10.1038/s41569-019-0241-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-019-0241-y

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing